Holen Sie sich die Stockscreener-App
5.775
1.62%
-0.075
Schlusskurs vom Vortag:
$5.85
Offen:
$5.81
24-Stunden-Volumen:
637.76K
Relative Volume:
0.47
Marktkapitalisierung:
$330.24M
Einnahmen:
$5.82M
Nettoeinkommen (Verlust:
$71.18M
KGV:
5.7912
EPS:
0.9972
Netto-Cashflow:
$-84.30M
1W Leistung:
-3.28%
1M Leistung:
-20.51%
6M Leistung:
+11.53%
1J Leistung:
-15.74%
1-Tages-Spanne:
$5.70
$5.9073
1-Wochen-Bereich:
$5.70
$6.03
52-Wochen-Spanne:
$4.00
$7.65
Abeona Therapeutics Inc Stock (ABEO) Company Profile
Firmenname
Abeona Therapeutics Inc
Sektor
Branche
Telefon
646-813-4701
Adresse
6555 CARNEGIE AVE, 4TH FLOOR, CLEVELAND, NY
Compare ABEO vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ABEO
Abeona Therapeutics Inc
|
5.775 | 334.53M | 5.82M | 71.18M | -84.30M | 0.9972 |
VRTX
Vertex Pharmaceuticals Inc
|
521.01 | 134.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
802.50 | 83.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,005.98 | 63.00B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
137.18 | 56.02B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
209.52 | 44.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
Abeona Therapeutics Inc Stock (ABEO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-02 | Fortgesetzt | Oppenheimer | Outperform |
| 2025-03-05 | Eingeleitet | Oppenheimer | Outperform |
| 2024-07-03 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-05-30 | Eingeleitet | Stifel | Buy |
| 2020-11-11 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2020-09-18 | Eingeleitet | B. Riley FBR | Buy |
| 2020-02-10 | Eingeleitet | SVB Leerink | Outperform |
| 2019-12-10 | Fortgesetzt | Cantor Fitzgerald | Neutral |
| 2019-08-15 | Herabstufung | Maxim Group | Buy → Hold |
| 2019-08-12 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2019-07-26 | Herabstufung | Mizuho | Buy → Neutral |
| 2019-06-27 | Eingeleitet | Mizuho | Buy |
| 2018-10-12 | Eingeleitet | Mizuho | Buy |
| 2018-06-05 | Eingeleitet | Seaport Global Securities | Buy |
| 2017-11-08 | Eingeleitet | SunTrust | Buy |
| 2017-10-16 | Bestätigt | H.C. Wainwright | Buy |
| 2017-10-11 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2017-10-10 | Eingeleitet | Citigroup | Buy |
| 2017-10-05 | Bestätigt | Maxim Group | Buy |
| 2017-09-15 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2017-07-18 | Bestätigt | Maxim Group | Buy |
| 2017-06-22 | Fortgesetzt | Jefferies | Buy |
| 2017-01-06 | Eingeleitet | Jefferies | Buy |
| 2016-09-29 | Bestätigt | Maxim Group | Buy |
Alle ansehen
Abeona Therapeutics Inc Aktie (ABEO) Neueste Nachrichten
Abeona at Cantor healthcare conference: slow launch, big rare-disease bet - Investing.com
ABEO Investors Have Opportunity to Join Abeona Therapeutics Inc. Fraud Investigation with SBS Law - Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc.ABEO - FinancialContent
Don't Ignore The Insider Selling In Abeona Therapeutics - simplywall.st
Responsive Playbooks and the ABEO Inflection - news.stocktradersdaily.com
ABEO Should I Buy - Intellectia AI
Abeona Therapeutics director Mark Alvino sells $87,966 in shares By Investing.com - Investing.com Australia
Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences - Yahoo Finance
Abeona Therapeutics director Mark Alvino sells $87,966 in shares - Investing.com
Director Mark Alvino Sells 15,000 Shares of Abeona Therapeutics Inc (ABEO) - GuruFocus
Abeona Therapeutics (ABEO) director sells 15,000 shares, still holds 62,065 - Stock Titan
Director plans Abeona (NASDAQ: ABEO) stock sale from equity awards - Stock Titan
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Stock Titan
Abeona Therapeutics Inc (ABEO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
H.C. Wainwright Maintains Abeona Therapeutics(ABEO.US) With Buy Rating, Maintains Target Price $20 - Moomoo
Abeona (ABEO) Stock: Gains 2.18% to Reach $6.09 in the Latest Reading; Range Check: the Supplied Trading Band Runs From $5.79 to $6.39 for the Current SessionCatalyst Driven Stocks - vinanet.vn
High Insider Ownership Growth Stocks To Watch In August 2026 - simplywall.st
Abeona’s (ABEO) Gene Therapy Launch Hits A Pivotal Reimbursement Milestone - Yahoo Finance
Abeona (ABEO) Latest Quarter: EPS Misses Its Estimate in the Latest Session; Market Reaction: The Market Price Declines 2.77% for the Current SessionRevenue Growth Outlook - vinanet.vn
Abeona (ABEO) Q2 2026 Earnings Call Transcript - AOL.com
ABEO: Zevaskyn Launch Gains Momentum - Smartkarma
Abeona Therapeutics Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
Abeona Therapeutics Inc (ABEO) (Q2 2026) Earnings Call Highlight - GuruFocus
Abeona Therapeutics (ABEO) Q2 Revenue Misses Estimates; Market Pricing Reflects Growth Uncertainty - GuruFocus
Abeona Therapeutics Inc (ABEO) (Q2 2026) Earnings Call Highlights: ZEVASKYN Revenue Surges 31% ... - Investing.com Canada
symbol__ Stock Quote Price and Forecast - CNN
Understanding the Setup: (ABEO) and Scalable Risk - news.stocktradersdaily.com
Abeona Therapeutics Insiders Sell US$2.9m Of Stock, Possibly Signalling Caution - Moomoo
Abeona Therapeutics (ABEO) Receives a Buy from Oppenheimer - The Globe and Mail
Abeona Therapeutics Stock Price Forecast. Should You Buy ABEO? - StockInvest.us
Montanova Capital (ABEO) reports 0.9% beneficial stake in Abeona Therapeutics - Stock Titan
ABEO Maintained by Oppenheimer -- Price Target Lowered to $21.00 - GuruFocus
Oppenheimer Adjusts PT on Abeona Therapeutics to $21 From $22, Maintains Outperform Rating - marketscreener.com
Abeona Therapeutics (ABEO) Q2 2026 Earnings Call: ZEVASKYN Revenue Rises 31% - TradingKey
Abeona Therapeutics (ABEO) Stock Faces Early Launch Strain Despite Revenue Traction - webull.com
Abeona Therapeutics earnings missed by $0.13, revenue fell short of estimates - Investing.com Canada
Abeona Therapeutics Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Abeona Therapeutics: Earnings Sell-Off Could Be A Buy Opportunity (NASDAQ:ABEO) - Seeking Alpha
Abeona Therapeutics (NASDAQ:ABEO) Issues Quarterly Earnings Results, Misses Estimates By $0.12 EPS - MarketBeat
Abeona Therapeutics Shares Fall After Q2 Miss - marketscreener.com
Abeona Therapeutics (ABEO) Advances ZEVASKYN Rollout Amid Mixed Valuation Signals - GuruFocus
Transcript : Abeona Therapeutics Inc., Q2 2026 Earnings Call, Aug 13, 2026 - marketscreener.com
Abeona Therapeutics Q2 Results: Revenue Rises 31% QoQ To $11.4 Million - scanx.trade
Abeona Therapeutics (ABEO) Stock Dips After Q2 Miss; Price-to-Sa - GuruFocus
Abeona Therapeutics Down Nearly 15%, On Pace For Largest Percent Decrease Since April 2024 -- Data Talk - Moomoo
Abeona Therapeutics Q2 2026 Earnings Call Transcript - Benzinga
Abeona Therapeutics Q2 Earnings Call Highlights - MarketBeat
Abeona stock drops after Q2 revenue miss (ABEO:NASDAQ) - Seeking Alpha
Earnings call transcript: Abeona Therapeutics misses Q2 2026 revenue view as shares fall - Investing.com
Abeona Therapeutics Reports Q2 2026 Results in Form 10-Q Filing - Kalkine Media
Abeona Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Finanzdaten der Abeona Therapeutics Inc-Aktie (ABEO)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.71%
2.84%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):